IP Library Granted Patent US 11,363,812
Granted Patent B2
US 11,363,812 · App. 16/472,962 · Granted Jun 21, 2022

Cell freezing medium for clinical use

Inventors: Fei Wang (Shanghai, CN); Jiaping He (Shanghai, CN); Dijun Zhao (Shanghai, CN); Victor Liu (Shanghai, CN); Dingzhu Yang (Shanghai, CN)
Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
A01N1/0221A01N1/0226C07K14/765C12N5/0037C12N5/0636C12N5/0663C12N2500/16C12N2500/32C12N2500/35C12N2500/38C12N2500/50C12N2500/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,363,812
App. No.
16/472,962
Granted
Jun 21, 2022
Kind
B2
Abstract

Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na + , K + , Mg + , Cl − , and CH 3 COO − ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.

Claims (28)

1. A cell cryopreservation solution for long-term storage of a mammalian stem cell, comprising:

a. a human albumin;

b. a cryoprotectant comprising one or more of dimethyl sulfoxide, glycerin, and ethylene glycol;

c. a salt buffer comprising Na + , K + , Mg 2+ , Cl − , and CH 3 COO − ions;

d. a vitamin; and

e. amino acids;

wherein the human albumin is present at a concentration of 1%-20% weight by volume (w/v),

the amino acids consist of a combination of glycine and arginine or a combination of leucine

and phenylalanine, and

the amino acids are independently present at a concentration of 0.1 mol/L-0.5 mol/L.

2. The cell cryopreservation solution of claim 1 , wherein the cryoprotectant is present at a concentration of 0.4 mol/L-2.2 mol/L.

3. The cell cryopreservation solution of claim 1 , wherein concentrations of Na + , K + , Mg 2+ , Cl − , and CH3COO − in the salt buffer are one or more concentrations selected from the group consisting of:

a concentration of the Na + ions being 0.1-0.2 mol/L;

a concentration of the K + ions being 5-10 mmol/L;

a concentration of the Mg 2+ ions being 1.5-5 mmol/L;

a concentration of the Cl − ions being 0.1-0.3 mol/L; and

a concentration of the CH 3 COO − ions being 40-60 mmol/L.

4. The cell cryopreservation solution of claim 1 , wherein the vitamin is present at a concentration of 50 mmol/L-150 mmol/L.

5. The cell cryopreservation solution of claim 1 , wherein the human albumin is selected from the group consisting of a plasma extracted human albumin, a recombinant human albumin, and a combination thereof.

6. The cell cryopreservation solution of claim 1 , wherein the vitamin is selected from the group consisting of vitamin A, vitamin B, vitamin C, vitamin E, vitamin K, and combinations thereof.

7. The cell cryopreservation solution of claim 1 , wherein the vitamin is vitamin C or vitamin E.

8. A mammalian cell mixture, comprising:

a mammalian cell and the cell cryopreservation solution of claim 1 .

9. A method for cryopreservation of a mammalian cell, comprising:

(i) mixing the mammalian cell to be cryopreserved with the cell cryopreservation solution of claim 1 , thereby obtaining a mammalian cell mixture;

(ii) cooling the mammalian cell mixture obtained in step (i) and storing the mammalian cell mixture in liquid nitrogen.

10. A kit for cell cryopreservation, comprising the cell cryopreservation solution of claim 1 .

11. The mammalian cell mixture of claim 8 , wherein the mammalian cell is a mesenchymal stem cell or a CAR-T cell.

Assignments (4)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062143/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2021
From: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.; CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 057892/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2020
From: WANG, FEI; HE, JIAPING; ZHAO, DIJUN; LIU, VICTOR; YANG, DINGZHU
To: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.; CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
Reel/Frame 053279/0015 →
Priority Claims (1)
CN 2016112049018 · Dec 23, 2016 · national
Continuity (1)
Related Publication 20190357525A1 · Nov 28, 2019
Cited By (7)
US 12,285,012 US 12,295,367 US 12,310,364 US 12,376,590 US 12,453,349 US 12,465,050 US 12,568,967